395. Real-World Insights of the Financial Metrics of a Long-Acting CAB/RPV Program

Open Forum Infectious Diseases 2026 Open access

Read full text
Authors: Joshua P Havens, Jennifer O’Neill, Maureen E Kubat, Sara Hurtado Bares, Nada A. Fadul, Jennifer M Davis, Joshua Lechner, Shawnalyn W Sunagawa
DOI: 10.1093/ofid/ofaf695.133
Cited by: 0

Abstract

Abstract Background Utilization of long-acting cabotegravir/rilpivirine (CAB/RPV) for people with HIV (PWH) has expanded since FDA approval in 2021, but barriers remain. Its economic impact is unclear yet vital for equitable access and sustainability. We assessed the economic outcomes of CAB/RPV in a Midwestern US HIV clinic.Figure 1.CAB/RPV financial outcomes.Represented as annual program income (PI)/hour/patient on CAB/RPV compared to oral bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for 2022-2024.*Denotes significant differences, p

Fields of Study & Subjects

HIV/AIDS Research and Interventions HIV/AIDS drug development and treatment Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Open Forum Infectious Diseases
Volume
13
Issue
Supplement_1
Publication date
1 January 2026
Language
EN